Additive inoculation influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients

Internal Medicine

Volumn 47, Issue 13, 2008, Pages 1189-1197

  Sumitani, Mitsuhiro ^a,b   Tochino, Yoshihiro ^b   Kamimori, Takao ^b   Fujiwara, Hiroshi ^b   Fujikawa, Terumichi ^b  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b YODOGAWA CHRISTIAN HOSPITAL   (Japan)

Author keywords

Community acquired pneumonia; COPD; Influenza vaccine; Pneumococcal vaccine; Streptococcus pneumoniae

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE; 23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE;

ADULT; AGED; ARTICLE; ASTHMA; BACTERIAL INFECTION; BRONCHIECTASIS; BRONCHIOLITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HOME OXYGEN THERAPY; HOSPITALIZATION; HUMAN; INFECTION RATE; JAPAN; JAPANESE; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PNEUMONIA; SPUTUM CULTURE; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; IMMUNIZATION; LONGITUDINAL STUDY; MIDDLE AGED; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; LONGITUDINAL STUDIES; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES;

EID: 49649096188     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.47.0799     Document Type: Article

References (43)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD Executive Summary. Am J Respir Crit Care Med 176: 532-555, 2007.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS; GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256-1276, 2001.
3. Rijneveld AW, Weijer S, Florquin S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis 189: 711-716, 2004.
4. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. IL-10 is an important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza infection. J Immunol 172: 7603-7609, 2004.
5. Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older, a prospective study. Lancet 357: 1008-1011, 2001.
6. Miyashita N, Matsushima T, Oka M; Japanese Respiratory Society. The JRS guidelines for the management of community-acquired pneumonia in adults, an update and new recommendations. Intern Med 45: 419-428, 2006.
7. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2: S27-S72, 2007.
8. Osaka Prefecture Public Health Office; Infectious Disease Prevention Division. Infection Outbreak Reports, The 20th Report, Osaka Prefecture, Japan. Osaka Prefecture, 2003.
9. Osaka Prefecture Public Health Office; Infectious Disease Prevention Division. Infection Outbreak Reports, The 21th Report, Osaka Prefecture, Japan. Osaka Prefecture, 2004.
10. Osaka Prefecture Public Health Office; Infectious Disease Prevention Division. Infection Outbreak Reports, The 22th Report, Osaka Prefecture, Japan. Osaka Prefecture, 2005.
11. Infection Outbreak Reports [database on the Internet]. Osaka Prefecture Public Health Office, Infectious Disease Prevention Division. c2004-[cited 2007 Mar 10]. Available from http://www.iph. pref.osaka.jp/ infection/
12. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 18: 362-368, 2001.
13. Macfarlane J, Holmes W, Gard P, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 56: 109-114, 2001.
14. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 50 Suppl S1: 25-37, 2002.
15. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270: 1826-1831, 1993.
16. Shapiro ED, Clemens JD. A controlled evaluation of the protective efficacy of pneumococcal vaccine for patients at high risk of serious pneumococcal infections. Ann Intern Med 101: 325-330, 1984.
17. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 108: 653-657, 1988.
18. Bolan G, Broome CV, Facklam RR, Plikaytis BD, Fraser DW, Schlech WF 3rd. Pneumococcal vaccine efficacy in selected populations in the United States. Ann Intern Med 104: 1-6, 1986.
19. Musher DM, Rueda-Jaimes AM, Graviss EA, Rodriguez-Barradas MC. Effect of pneumococcal vaccination: a comparison of vaccination rates in patients with bacteremic and nonbacteremic pneumococcal pneumonia. Clin Infect Dis 43: 1004-1008, 2006.
20. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al; EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 43: 860-868, 2006.
21. Vila-Corcoles A, Ochoa-Gondar O, Llor C, Hospital I, Rodriguez T, Gomez A. Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects. Eur Respir J 26: 1086-1091, 2005.
22. WHO. The Weekly Epidemiological Record 78: 110-119, 2003.
23. Jackson LA, Neuzil KM, Yu O, et al; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348: 1747-1755, 2003.
24. Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 4: CD000422, 2003.
25. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351: 399-403, 1998.
26. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 83: 425-430, 1987.
27. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 17 Suppl 1: S91-S93, 1999.
28. Chiba H, Ohrui T, Matsui T, Fukushima T, Sasaki H. Benefits of pneumococcal vaccination for bedridden patients. J Am Geriatr Soc 52: 1410, 2004.
29. Oishi K, Yoshimine H, Watanabe H, et al. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology 11: 429-436, 2006.
30. Fukumi H, Kimura M, Kato S, et al. Clinical report on safety and antigenicity of 23-valent pneumococcal polysaccharide vaccine. Kansenshogaku Zasshi 58: 495-511, 1984 (in Japanese).
31. Saito W, Nagai H, Suzuki J, et al. Capsular polysaccharide anti-bodies after pneumococcal polysaccharide vaccination in patients with chronic respiratory disease. Nihon Kokyuki Gakkai Zasshi 43: 277-282, 2005 (in Japanese).
32. Artz AS, Ershler WB, Longo DL. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 16: 308-318, 2003.
33. García-Vázquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 164: 1807-1811, 2004.
34. Tzeng DH, Lee YL, Lin YH, Tsai CA, Shi ZY. Diagnostic value of the Binax NOW assay for identifying a pneumococcal etiology in patients with respiratory tract infection. J Microbiol Immunol Infect 39: 39-44, 2006.
35. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Matsushima T. Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. Respiration 74: 387-393, 2007.
36. Mufson MA, Krause HE, Schiffman G. Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine. Proc Soc Exp Biol Med 173: 270-275, 1983.
37. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270: 1826-1831, 1993.
38. Chen M, Hisatomi Y, Furumoto A, et al. Comparative immune responses of patients with chronic pulmonary diseases during the 2 year period after pneumococcal vaccination. Clin Vaccine Immunol 14: 139-145, 2007.
39. Almirall J, Bolibar I, Balanzo X, Gonzalez CA. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 13: 349-355, 1999.
40. Monso E, Garcia-Aymerich J, Soler N, et al. EFRAM Investigators. Bacterial infection in exacerbated COPD with changes in sputum characteristics. Epidemiol Infect 131: 799-804, 2003.
41. Groenewegen KH, Wouters EF. Bacterial infections in patients requiring admission for an acute exacerbation of COPD; a 1-year prospective study. Respir Med 97: 770-777, 2003.
42. Roche N, Kouassi B, Rabbat A, Mounedji A, Lorut C, Huchon G. Yield of sputum microbiological examination in patients hospitalized for exacerbations of chronic obstructive pulmonary disease with purulent sputum. Respiration 74: 19-25, 2007.
43. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 173: 1114-1121, 2006.